Home

WIN 2017 Symposium is endorsed by:

asco-logo
eso-logo

Symposium WIN2017 Key speakers

    Interviews with WIN 2017 speakers by Ecancer

    To watch all videos with the WIN 2017 speakers please click here »

    Dr. Richard L. Schilsky
    Chairman Scientific Advisory Board WIN

    Prof. Jack Lee
    University of Texas MD Anderson Cancer Center, USA

    Prof. Martine J. Piccart-Gebhart
    Director of Medicine, Institute Jules Bordet, Brussels, Belgium

    WIN Symposium Program

    The WIN 2017 Symposium program will elaborate the theme ‘Expediting Global Innovation in Precision Cancer Medicine’  in six plenary sessions, divided over two days of meetings. The program will be supplemented by poster viewing sessions, not overlapping with the plenary sessions, and a plenary poster awarding ceremony.

    José Baselga
    Memorial Sloan Kettering, USA

    Keynote Opening Lecture
    Genomic-driven Clinical Studies in Breast Cancer

    René Bernards
    NKI, The Netherlands

    Synthetic lethality as a basis to select drug combinations in animal models and in cancer patients

    Martine J. Piccart-Gebhart
    Institut Jules Bordet, Belgium

    Biomarker Research in Breast Cancer: A Journey into the Desert

    Daniel F. Hayes
    University of Michigan Comprehensive Cancer Center, USA

    Incorporating Liquid Biopsies into Clinical Trials to Select and Monitor Participants

    WIN 2017 Organizing Committee
    Chairs: Gerald Batist (Canada) and Thomas Tursz (France)
    Members: Lisa Hutchinson (UK), Razelle Kurzrock (USA), Brian Leyland-Jones (USA), John Mendelsohn (USA), Amir Onn (Israel), Richard L. Schilsky (USA), Josep Tabernero (Spain), Vladimir Lazar (France), Catherine Bresson (France)

    Monday June 26, 2017

    WELCOME

    8:30 – 8:40


    8:40 – 9:10

    Welcome and opening remarks
    John Mendelsohn, University of Texas MD Anderson Cancer Center, USA

    Keynote opening lecture: Genomic-driven Clinical Studies in Breast Cancer
    José Baselga, Memorial Sloan Kettering, USA

    SESSION 1: INNOVATION IN CLINICAL TRIAL DESIGN

    9:10 – 9:30


    9:30 – 9:50


    9:50 – 10:10


    10:35 – 10:55


    10:55 – 11:40

    Fit for Purpose: Using Biomarkers and Diagnostics in clinical trials, to Impact Personalized Care
    Laura Esserman, University of California San Francisco, Carol Franc Buck Breast Care Center, USA

    Shifting the Clinical Trial Paradigm to Keep Pace with Rapidly Changing Cancer Biology
    Donald A. Berry, University of Texas MD Anderson Cancer Center, USA

    Bayesian Adaptive Designs for Precision Medicine: Promise, Progress, and Challenge
    J. Jack Lee, University of Texas MD Anderson Cancer Center, USA

    Redesigning Clinical Trials in the Era of Precision Medicine: What the Science Demands
    Razelle Kurzrock, University of California, San Diego Moores Cancer Center, USA

    Open Forum and Debate:  New trends in clinical trial design
    Moderated by Razelle Kurzrock, University of California, San Diego Moores Cancer Center, USA and Brian Leyland Jones, Avera Cancer Institute, USA

    SESSION 2: NEW AVENUES FOR TARGET DISCOVERY

    11:45 – 12:10


    12:10 – 12:35


    12.35 – 13.00

    Toward full integration of patient-related data into drug and biomarker discovery: a retro-translational process?
    Patrice P. Denèfle, Institut Roche for Research & Translational Medicine, France

    Chromatin dynamics – epigenetic parameters and cellular fate
    Geneviève Almouzni, Institut Curie, France

    DNA damage response pathway inhibition – a pipeline and the phase 1 experience
    Giorgio Massimini, Merck KGaA, Germany

    SESSION 3: IMMUNOLOGICAL APPROACH TO PERSONALIZED MEDICINE

    14:00 – 14:25


    14:25 – 14:50


    14:50 – 15:15


    15:40 – 16:05


    16:05 – 16:30


    16:30 – 16:55


    16:55 – 17:15

    17.15 – 18.00

    19:00

    New biomarkers for response to immunotherapy
    Antoni Ribas, University of California Los Angeles, USA

    Precision medicine enabled histology agnostic development of immune-oncology agents
    Roy D. Baynes, Merck Sharpe & Dohme, USA

    The Complex Challenges of Stratifying Patients for Immunotherapy
    Steve Anderson, Covance, USA

    Apoptosis, cancer and immunity; therapeutic implications
    Guido Kroemer, Gustave Roussy, France

    Patient-specific peptide vaccines
    Hans-Georg Rammensee, University of Tübingen, Germany

    Open Forum and Debate:  Place of immunotherapy approaches in precision cancer care
    Moderated by Antoni Ribas, University of California Los Angeles, USA and Jean-Yves Blay, Centre Léon Bérard, France

    Awarding ceremony best-poster awards

    Welcome reception and poster viewing

    Symposium dinner cruise

    Tuesday June 27, 2017

    SESSION 4: NEXT GREAT STEPS IN CANCER THERAPY

    8:30 – 8:55


    8:55 – 9:20


    9:20 – 9:45


    9:45 – 10:10

    Novel models to personalize cancer therapeutics
    Olli Kallioniemi,  Science for Life Laboratory, Karolinska Institutet, Stockholm & Institute for Molecular Medicine Finland (FIMM), Finland

    Omics Convergence (Proteogenomics) in Cancer Research: New Opportunities in Cancer Biology and Precision Medicine
    Henry Rodriguez, National Cancer Institute, USA

    Genomic analysis of childhood tumors; biological and therapeutic implications
    Peter Lichter, DKFZ, Germany

    Cancer Genome Sequencing in a Multi-Institutional Clinical Setting “The MASTER Study of the German Cancer Consortium”
    Stefan Fröhling, DKFZ, Germany

    SESSION 5: PREDICT: WHAT AND HOW?

    10:40 – 11:05


    11:05 – 11:30


    11:30 – 11:55


    11:55 – 12:20

    Biomarker Research in Breast Cancer: A Journey into the Desert
    Martine J. Piccart-Gebhart, Institut Jules Bordet, Belgium

    Prognostic, predictive and clinically relevant biomarkers – A pharma perspective
    Jean-François Martini, Pfizer Inc., USA

    Augmented Intelligence in the clinical set of Precision Oncology – A IBM Watson perspective
    Vanessa V. Michelini, IBM Watson Health, USA

    Combining immune-based therapies with TKIs in melanomas
    Caroline Robert, Gustave Roussy, France

    SESSION 6: USING NEW KNOWLEDGE IN CLINICAL TRIALS

    13:40 – 14:05


    14:05 – 14:30


    14:30 – 14:55


    14:55 – 15:20


    15:20 – 15:45

    Synthetic lethality as a basis to select drug combinations in animal models and in cancer patients
    René Bernards, NKI, The Netherlands

    Incorporating Liquid Biopsies into Clinical Trials to Select and Monitor Participants
    Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, USA

    Molecular medicine in lung cancer
    Reinhard Büttner, University Hospital of Cologne, Germany

    The INFORM program – personalizing pediatric oncology on a population-based level in Germany
    Stefan Pfister, DKFZ, Germany

    Genomic Predictors of Treatment Response in Prostate Cancer: A New Era
    Robert G. Bristow, Princess Margaret Cancer Centre, Canada

    ROUNDTABLE

    16:10 – 16:45

    Challenges of real world implementation of Precision Medicine, and implications for other diseases

    Moderators:
    Lisa Hutchinson, Nature Publishing Group, UK
    Thomas Tursz, Fondation ARC, France

    Participants:
    Andrea Califano, Columbia University, USA
    Martine J. Piccart-Gebhart, Institut Jules Bordet, Belgium
    Richard L. Schilsky, ASCO, USA
    Francesco De Lorenzo, ECPC, Belgium

    CONCLUDING REMARKS

    16:45 – 17:10

    Systems Medicine, Big Data and Scientific Wellness are transforming Healthcare
    Leroy Hood, Institute for Systems Biology, USA

    Please check back soon for the speakers’ biographies as they become available.

    Report WIN 2015 Symposium

    For an extensive meeting report by Dr. Richard L. Schilsky visit ecancer. Below is a brief summary report for your quick orientation.

    The WIN 2015 Symposium, a two-day symposium on precision cancer medicine offered by WIN Consortium, attracted delegates from 36 countries worldwide. The overarching theme this year was Novel targets, innovative agents, advanced technologies: A WINning strategy? This theme was elaborated in various plenary sessions with over 25 internationally renown speakers, a round table of global pharma and academic experts on Overcoming resistance through combined therapies, moderated by Richard L. Schilsky, ASCO’s Chief Medical Officer and WIN Consortium’s Scientific Advisory Board chair, and poster presentations. Many presentations (PDF) can be viewed on this website.

    James Allison, presenter of a keynote lecture

    James Allison, presenter of a keynote lecture

    Keynote lectures were presented by John Mendelsohn, Chairman, WIN Consortium, on The Era of Precision Cancer Medicine: A worldwide effort and challenge, James Allison, The University of Texas MD Anderson Cancer Center, on Targeting immune mechanisms,Andrea Califano, Columbia University, on  A systems biology approach to precision cancer medicine, James Doroshow, U.S. National Cancer Institute (NCI) on A perspective on NCI’s strategy and trials, and Francesco Pignatti, European Medicines Agency (EMA) on The EMA adaptive pathways approach to improve timely access for patients to new medicines. 

    Richard L. Schilsky, ASCO’s Chief Medical Officer and Chairman of WIN Consortium’s SAB, moderated a lively round-table discussion of pharma and academic experts on Overcoming resistance through combined therapies.

    WIN Consortium encourages the submission of high-quality abstracts on precision cancer medicine by awarding best-poster awards to a few posters presented at the annual WIN Symposium.

    News

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

    What experts say about the WIN 2017 Symposium

    John Mendelsohn
    Chairman of the WIN Consortium
    What is the WIN Consortium?

    Vladimir Lazar
    Chief Scientific and Operating Officer, WIN Consortium
    Global horizons of the WIN Consortium

    Logistics

    For more information about registration, abstract management and your trip to Paris, please click on the tabs below.

    Venue

    WIN 2017 will be held at Hotel Novotel Paris Tour Eiffel , 61 Quai de Grenelle, 75015 Paris, France.

    NOVOTE~1

    The venue is located in the heart of Paris on the borders of the Seine river and a short distance from the Eiffel Tower. The hotel is also close to the Champs-Elysées, the Louvre and Notre-Dame.

    3546a00

    WIN 2017 delegates may book hotel accommodation at the venue at the special delegate rate, giving them the benefit of having the symposium facilities and their hotel room under one roof. Hotel accommodation at the Hotel Novotel Paris Tour Eiffel can be booked via a special booking site. Please click here for the official booking website.

    Registration

    Online registration is now open.

    Registration fees (in €)Until March 31April 1 until June 24As of June 24 and on-site
    Non-profit450550800
    Industry7009001000
    Students, residents in training
    Student/resident status to be documented
    200300400

    Groups

    For group registration, contact the Symposium Secretariat.

    Cancellation

    Cancellation of registration has to be made in writing to the Symposium Secretariat. If a cancellation is received before or on June 19, 2017, reimbursement of the registration fee, minus €100,- handling charges, will be made. After this date, or if registrants fail to attend the symposium for any reason whatsoever, regrettably no refund can be made.

    Scholarships and travel grants

    Unfortunately, no scholarships, travel grants or waiver of registration fees can be provided to any WIN 2017 delegate.  Students and residents in training may register at strongly reduced fees, provided they can document student/resident status.

    Press policy

    Representatives of the press and media agencies with media credentials are welcome to attend the WIN 2017 Symposium. Contact the Symposium Secretariat for details of media registration.

    By registering as media representatives for WIN 2017, journalists, press photographers, film crews and other members of the press accept that they must comply with the WIN 2017 Press Policy. Failure to do so may result in the immediate withdrawal of press registration.

    Picture taking, audio/video recording and/or filming at the WIN 2017 venue without prior permission of the WIN 2017 Symposium organizers are prohibited. Requests for interviews of speakers or faculty should be sent to the Symposium Secretariat.

    Media partnership

    The WIN 2017 Symposium Committee is open to discussing media partnerships with media active in the field of cancer and precision medicine. Contact the Symposium Secretariat to post your interest in a media partnership.

    Abstracts

    The regular abstracts submission is closed.

    Frontiers in Oncology

    Abstracts submitted for WIN Symposium 2017 and accepted for presentation, including invited abstracts, will be published in Frontiers in Oncology. Frontiers in Oncology is an open-access journal that aims at publishing research across the field of oncology. It is indexed in PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, and Chemical Abstracts Service (CAS).

    You will find the abstract publication after WIN Symposium 2017 here.

    Abstracts per plenary session and poster session:

    –       Plenary session 1: Innovation In Clinical Trail Design
    –       Plenary session 2: New avenues for target discovery
    –       Plenary session 3: Immunological approach to personalizaed
    –       Plenary session 4: Next great steps in cancer therapy
    –       Plenary session 5: Predict: what and how
    –       Plenary session 6: Using new knowledge in clinical trails

    –        Poster session 1: Bioinformatics
    –        Poster session 2: Biomarkers (prognostic and predictive)
    –        Poster session 3: Clinical trial design
    –        Poster session 4: Diagnostics
    –        Poster session 6: Drug resistance and modifiers
    –        Poster session 7: Early diagnosis of cancer
    –        Poster session 8: Experimental therapies – clinical
    –        Poster session 9: Experimental therapies – preclinical
    –        Poster session 10: Genetics, genomics and proteomics
    –        Poster session 11: New combinations (agents and modalities)
    –        Poster session 12: New treatment strategies
    –        Poster session 13: Other topics (WIN Symposium related)
    –        Poster session 14: Preclinical test models

    European CME credits

    The WIN 2017 Symposium is granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

    The EACCME is an institution of the European Union of Medical Specialists (UEMS). The UEMS has agreements based on the mutual recognition of credit points with the American Medical Association (AMA) and the Royal College of Physicians and Surgeons of Canada.

    Sponsoring the event

    WIN Consortium, organizer of the WIN Symposium series, invites financial support from corporations, foundations, and other organizations to help defray the costs of organizing WIN 2017. Various attractive benefits are available to sponsoring and supporting entities. All sponsoring contributions will be considered unrestricted educational grants towards the WIN 2017 Symposium.

    Educational grants for which the donator receives no specific benefits other than grant acknowledgements in association with WIN 2017 are also welcome.

    If you are interested in discussing a sponsorship arrangement, or if you have other suggestions for a specific sponsorship arrangement, please contact the WIN 2017 Symposium Secretariat.